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Abstract Regulation of multidrug resistance-associated protein
(MRP2) expression in response to dexamethasone (DEX) was
analyzed using mainly primary rat hepatocytes. Enhanced levels
of MRP2 mRNAs associated with increased amounts of a 190
kDa MRP2 were found in cultured DEX-treated hepatocytes;
similarly, administration of DEX to rats (100 mg/kg, i.p.) led to
a marked increase of hepatic amounts of MRP2 mRNAs.
Maximal induction of MRP2 expression in DEX-treated
primary hepatocytes was reached with 1035 M DEX, a
concentration higher than that (1037 M) required for maximal
up-regulation of tyrosine aminotransferase (TAT), a typical
glucocorticoid receptor-regulated enzyme. In addition, the anti-
glucocorticoid compound RU486 failed to inhibit MRP2
induction caused by DEX whereas it fully blocked that of
TAT. These findings therefore demonstrate that DEX is a potent
inducer of MRP2 expression in rat hepatocytes through a
mechanism that seems not to involve the classical glucocorticoid
receptor pathway.
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1. Introduction
Multidrug resistance-associated protein 2 (MRP2), also
called canalicular multi-speci¢c organic anion transporter
(cMOAT), is a 190 kDa plasma membrane phosphoglycopro-
tein [1,2]. It is predominantly expressed at the biliary pole of
hepatocytes, but has also been evidenced in kidney and intes-
tine [3]. MRP2 is thought to mediate the transport of various
organic anions, including glucuronate, sulfate and glutathione
conjugates, across the canalicular hepatocyte membrane [1,2].
Mutant strains of rats lacking MRP2 expression such as the
transport de¢cient (TR3) wistar rat and the Eisai hyperbili-
rubinemic rat (EHBR) therefore display a de¢ciency in the
biliary secretion of conjugates of xenobiotics or endogenous
compounds such as bilirubin [1,3]. Similarly, in humans, the
Dubin-Johnson-syndrome, an autosomal dominant hereditary
disease characterized by a chronic hyperbilirubinemia, is also
caused by an absence of MRP2 due to a mutation in the gene
[4].
MRP2 belongs to the ATP-binding cassette (ABC) trans-
porter superfamily which comprises other drugs e¥ux pumps
such as P-glycoprotein (P-gp) and multidrug resistance-asso-
ciated protein 1 (MRP1) [5]. Like these latter membrane pro-
teins, MRP2 is thought to transport some anti-cancer drugs
such as vinblastine out of cells and may therefore confer some
drug resistance to tumor cells [6].
Regulation of hepatic expression of MRP2 is poorly under-
stood. Recent studies have however demonstrated that MRP2
levels are down-regulated in the liver in response to endotoxin
whereas exposure of cultured rat hepatocytes to 2-acetylami-
no£uorene or cycloheximide results in an increased expression
of MRP2 [7^9]. Such treatments have also been found to alter
the levels of P-gp found in rat hepatocytes [8,10,11], thus
suggesting that some factors, i.e. xenobiotics or endogenous
compounds, may regulate both MRP2 and P-gp. Interestingly,
expression of the latter pump has been shown to be strongly
down-modulated in primary cultured rat hepatocytes treated
by DEX [12]. This potent glucocorticoid is also known to
regulate other liver proteins such as tyrosine aminotransferase
(TAT) through its binding to the glucocorticoid receptor (GR)
and subsequent interaction with glucocorticoid response ele-
ments found in the 5P-£anking region of responsive genes
[13,14]. In the present study, we have investigated whether
DEX may also regulate MRP2 levels using mainly primary
rat hepatocyte cultures that are well recognized as a suitable
cellular model for analyzing regulation of hepatic transporters
[9,10,12]. Our results indicated that the glucocorticoid com-
pound strongly induced MRP2 expression in rat hepatocytes
through a mechanism that seems not to involve the GR path-
way.
2. Materials and methods
2.1. Chemicals
Dexamethasone, actinomycin D, clotrimazole and pregnenolone
16K-carbonitrile (PCN) were purchased from Sigma (St Louis, MO,
USA). RU-486 (also termed mifepristone) was kindly provided by
Roussel-Uclaf (Romainville, France).
2.2. Animal treatment
Male Sprague-Dawley rats weighing 180^200 g were treated with
DEX (100 mg/kg, i.p.) dissolved in corn oil. Control rats received only
corn oil. Rats were killed 8 h after administration of the glucocorti-
coid. Livers were removed and immediately stored at 380‡C until use.
2.3. Cell isolation and culture
Hepatocytes from adult male Sprague-Dawley rats weighing 180^
200 g were isolated by perfusion of the liver as previously described
except that a liberase solution was used for dissociation of liver cells
instead of a collagenase solution [12]. Cells were seeded at a density of
105 cells/cm2 in plastic dishes in Williams’ E medium supplemented
with 0.2 mg/ml bovine serum albumin, 10 mg/ml bovine insulin and
10% (v/v) fetal calf serum. The medium was discarded 4 h after cell
seeding and cells were thereafter maintained in serum-free medium.
For treatment of the cultures, DEX, actinomycin D, clotrimazole,
PCN and RU486, dissolved in dimethylsulfoxide, were added in the
serum-free medium; controls received the same volume of solvent
which did not exceed 0.1% (v/v). At the concentrations used, neither
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DEX nor the xenobiotics used were found to have cytotoxic e¡ects
towards primary hepatocytes as assessed by light microscopic exami-
nation of the cultures.
2.4. Isolation of total RNAs and Northern blot analysis
Total RNAs were extracted from cultured hepatocytes or liver frag-
ments by the guanidinium thiocyanate/cesium chloride method of
Chirgwin et al. [15] as modi¢ed by Raymondjean et al. [16]. For
Northern blotting, 10 Wg of total RNAs was subjected to electropho-
resis in a denaturing formaldehyde/agarose gel and transferred onto
Hybond-N+ sheets (Amersham). The sheets were pre-hybridized, hy-
bridized with 32P-labeled probes, washed, dried and autoradiogra-
phied at 380‡C. MRP2 mRNAs were analyzed with a 0.86 kb rat
MRP2 cDNA probe generated by reverse transcription-polymerase
chain reaction as previously reported [17] whereas TAT and P-gp
mRNAs were detected using a rat TAT cDNA probe, kindly provided
by Dr. L. Corcos (INSERM U517, Dijon, France), [18] and the
pCHP1 probe [19], respectively. Equal gel loading and e⁄ciency of
the transfer were checked using an 18S rRNA probe.
2.5. Preparation of crude membranes and Western blotting
Crude membranes were prepared from cultured hepatocytes by dif-
ferential centrifugation as described by Germann et al. [20]. Mem-
brane proteins were then separated on a 7.5% polyacrylamide gel
and electrophoretically transferred to nitrocellulose sheets. Sheets
were blocked for 2 h with Tris-bu¡ered saline containing 3% bovine
serum albumin and 1% milk and were next incubated with the poly-
clonal anti-MRP2 antibody RM2. This antibody was developed
through rabbit immunization against the peptide EAGIENVNHTEL
corresponding to the C-terminal portion of rat MRP2. The anti-
MRP2 EAG15 antibody, kindly provided by Dr. D. Keppler
(Deutsches Krebsforschungszentrum, Heidelberg, Germany) was also
used as primary antibody instead of RM2. A peroxidase-conjugated
anti-rabbit antibody was thereafter used as secondary antibody. After
washing, blots were developed by chemiluminescence using the Amer-
sham ECL detection system. Control blot was performed in parallel
using the same protocol, except that anti-MRP2 antibody was re-
placed by non-immune rabbit serum.
3. Results
Primary rat hepatocytes were ¢rst treated by various con-
centrations of DEX ranging from 10312 to 1034 M for 48 h.
Northern blot analysis indicated that the glucocorticoid com-
pound strongly enhanced MRP2 mRNA levels in a dose-de-
pendent manner (Fig. 1). Indeed, this e¡ect started with 1038
M DEX and was maximal when the glucocorticoid was used
at 1035 M or 1034 M. As previously reported [1,2], several
MRP2 mRNAs of di¡erent sizes, especially of 5.5 kb and 7.5
kb, were evidenced on the blot (Fig. 1); they probably repre-
sent alternative mRNA splicing variants with di¡erent 3P-un-
translated region lengths [21] and their relative proportion
appeared not to be obviously modi¢ed in response to DEX
whatever doses were used. Dexamethasone was also found to
down-regulate P-gp mRNA levels and to increase those of
TAT mRNAs in primary hepatocytes (Fig. 1). Analysis of
the dose-response corresponding to this induction of TAT
transcripts indicated that, in contrast to MRP2 mRNAs,
those of TAT were maximally induced when DEX was used
at 1037 M and higher concentrations of the glucocorticoid did
not result in an higher increase of TAT mRNA amounts.
Time-course of the induction of MRP2 mRNA levels occur-
ring in response to 1034 M DEX in primary hepatocytes
was further determined by Northern blot analysis. As indi-
cated in Fig. 2, MRP2 mRNA amounts were clearly up-regu-
lated in primary hepatocytes as early as a 4 h exposure to the
glucocorticoid compound whereas they were not obviously
altered by shorter treatments. Longer exposures (24^48 h) to
DEX resulted in maximal induction of MRP2 transcripts (Fig.
2).
Total RNAs were next prepared from livers of rats treated
by i.p. injection of DEX. As indicated in Fig. 3, DEX-treated
rats displayed enhanced hepatic amounts of MRP2 mRNAs
when compared to control rats.
Crude membrane fractions were prepared from cultured
hepatocytes exposed to 1034 M DEX for 48 h and were
used to investigate MRP2 expression by Western blot analysis
(Fig. 4). An RM2 antibody-reactive band of 190 kDa corre-
sponding to MRP2 was markedly overexpressed in DEX-
treated hepatocytes when compared to their untreated coun-
terparts. A similar 190 kDa band was also observed in DEX-
treated rat hepatocytes when the polyclonal antibody EAG15
Fig. 1. Dose-dependent induction of MRP2 mRNAs in primary
hepatocytes exposed to DEX. A: Each lane contained 10 Wg total
RNAs isolated from primary rat hepatocytes either untreated
(UNT) or exposed to various concentrations of DEX ranging from
10312 to 1034 M. RNAs were transferred to Hybond N+ sheets
after electrophoresis and hybridized with MRP2, TAT, P-gp and
18S probes. B: Increases in MRP2 and TAT mRNA levels occur-
ring in response to various doses of DEX were quanti¢ed by densi-
tometric analysis. Results were expressed as percentage of maximal
increase of MRP2 or TAT mRNAs, obtained with 1035 and 1037
M DEX, respectively. The data shown are representative of two in-
dependent experiments.
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was used instead of RM2 whereas this band was not present
in control blots performed using non-immune rabbit serum as
primary antibody (data not shown).
The e¡ect of actinomycin D, a known inhibitor of tran-
scription, on DEX-mediated induction of MRP2 mRNA lev-
els was further evaluated by Northern blot analysis. In this
experiment, actinomycin D was used at 3 Wg/ml for 8 h and
such a treatment has been previously shown to decrease RNA
synthesis levels to less than 1% of values found in untreated
liver cells [22]. As indicated in Fig. 5A, actinomycin D fully
suppressed MRP2 mRNA increase occurring in response to
DEX in primary hepatocytes whereas it did not a¡ect basal
levels of MRP2 transcripts.
We then examined the e¡ect of RU486, an anti-glucocorti-
coid compound acting through interaction with the GR re-
ceptor [23], on DEX-related increase of MRP2 mRNA levels.
RU486, used at 1035 M, did not block induction of MRP2
transcripts occurring in response to DEX in cultured hepato-
cytes (Fig. 5B). Moreover, RU486-treated hepatocytes were
found to display increased amounts of MRP2 mRNAs when
compared to their untreated counterparts; such an increase
was however weaker than that occurring in response to
DEX. By contrast, treatment by the anti-glucocorticoid com-
pound did not up-regulate TAT mRNA levels in primary
hepatocytes and was found to strongly inhibit induction of
TAT mRNA levels caused by DEX (Fig. 5B).
Finally, we analyzed MRP2 mRNA levels in primary hep-
atocytes treated by the antimycotic drug clotrimazole or the
Fig. 2. Time-course of MRP2 mRNA induction in response to
DEX. Each lane contained 10 Wg total RNAs isolated from primary
rat hepatocytes either untreated (UNT) or exposed to 1034 M DEX
for various lengths of time (1^48 h). RNAs were transferred to Hy-
bond N+ sheets after electrophoresis and hybridized with MRP2
and 18S probes.
Fig. 3. Induction of MRP2 mRNA levels in liver of DEX-treated
rats. Each lane contained 10 Wg total RNAs isolated from the liver
of control rats (UNT) or DEX-treated rats. RNAs were transferred
to Hybond N+ sheets after electrophoresis and hybridized with
MRP2 and 18S probes. The data shown are representative of the
analysis of four rats in each group (control and DEX-treated).
Fig. 4. Western blot analysis of crude membrane proteins obtained
from DEX-treated hepatocytes. Crude membrane fractions were pre-
pared from primary rat hepatocytes either untreated (UNT) or ex-
posed to 1034 M DEX for 48 h. Membrane proteins (50 Wg) were
transferred onto a nitrocellulose sheet after electrophoresis. After in-
cubation with RM2 antibody raised against MRP2, the blot was de-
veloped as described in Section 2.
Fig. 5. E¡ect of actinomycin D (A) and RU486 (B) on DEX-medi-
ated MRP2 mRNA induction. A: Each lane contained 10 Wg total
RNAs isolated from primary rat hepatocytes either untreated
(UNT) or exposed to 1034 M DEX or 3 Wg/ml actinomycin D
(ACT) or co-treated with DEX and ACT for 8 h. RNAs were
transferred to Hybond N+ sheets after electrophoresis and hybri-
dized with MRP2 and 18S probes. B: Each lane contained 10 Wg
total RNAs isolated from primary rat hepatocytes either untreated
(UNT) or exposed to 1037 M DEX or 1035 M RU486 or co-treated
with DEX and RU486 for 48 h. RNAs were transferred to Hybond
N+ sheets after electrophoresis and hybridized with MRP2, TAT
and 18S probes.
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anti-glucocorticoid PCN. Indeed, these two drugs have previ-
ously been shown to induce expression of some DEX-regu-
lated detoxifying enzymes such as cytochromes P450 (CYP)
3A1/2 [24]. As shown in Fig. 6, clotrimazole and PCN were
also found to increase MRP2 mRNA levels in primary rat
hepatocytes.
4. Discussion
The results reported in the present study demonstrated that
DEX, a potent glucocorticoid compound, markedly up-regu-
lates MRP2 expression in rat hepatocytes. Indeed, treatment
by DEX was found to strongly enhance MRP2 mRNA levels
in both DEX-treated primary hepatocytes and liver of DEX-
treated rats. Such an increase in MRP2 transcripts occurred
relatively rapidly since it started in primary hepatocytes after
a 4 h exposure to the glucocorticoid compound. Moreover, it
was associated with elevated levels of a 190 kDa MRP2 in
cultured hepatocytes exposed to DEX as assessed by Western
blot analysis ; similarly, DEX-treated rats were also found to
display enhanced hepatic levels of MRP2 (data not shown).
By contrast, DEX was demonstrated to down-regulate expres-
sion of the cationic drug transporter P-gp in primary hepato-
cytes as previously reported [12]. Taken together, these data
therefore indicate that DEX di¡erently alters expression of
drug transporters in hepatocytes. Similarly, levels of drug me-
tabolizing enzymes found in rat hepatocytes may be either up-
regulated or down-regulated in response to glucocorticoids
according to the enzyme. Expression of some cytochromes
P-450 (CYP) such as CYP 3A1/2 is thus increased by DEX
[13,24] whereas levels of glutathione S-transferase pi are de-
creased in DEX-treated rat hepatocytes [12].
The action of DEX on MRP2 mRNA levels in primary
hepatocytes requires active transcription since it was fully
blocked by actinomycin D. By contrast, it was not inhibited
by the anti-glucocorticoid RU486 whereas this compound
fully blocked DEX-mediated induction of TAT mRNAs.
These results suggests that GR, which plays a major role in
regulation of TAT by DEX [25], is likely not involved in the
induction of MRP2 expression by the glucocorticoid com-
pound; such a regulation may therefore be included in non-
classical glucocorticoid-mediated processes. This conclusion is
moreover fully supported by the comparison of the dose-
responses for MRP2 and TAT, which clearly demonstrated
that maximal induction of MRP2 required higher doses of
DEX than those needed for TAT, a typical GR-regulated
enzyme.
The pro¢le of the dose-response for MRP2 up-regulation in
response to DEX is in fact close to that observed for the
induction of CYP 3A1/2 in rat liver cells. Indeed, maximal
induction of CYP 3A1/2 in primary rat hepatocytes also re-
quired the use of elevated concentrations of glucocorticoids
[13]. Another feature shared by both hormone-mediated
MRP2 and CYP 3A1/2 regulations is linked to the e¡ect of
RU486; indeed, treatment by this anti-glucocorticoid com-
pound, that was demonstrated in the present study to increase
MRP2 transcript levels in primary hepatocytes, has also been
found to up-regulate CYP3 A1/2, although, as for MRP2, to a
smaller extent than exposure to DEX [24]. Interestingly, the
increase of CYP 3A1/2 contents in DEX- or RU486-treated
hepatocytes has been recently shown to be mediated by a new
member of the nuclear hormone receptor superfamily termed
pregnane X receptor (PXR) [26]. Indeed, DEX and RU486
have been demonstrated to activate PXR bound to a hormone
response element located in the 5P-£anking region of the rat
CYP 3A1/2 gene and subsequently to induce the transcription
of this gene [26,27]; glucocorticoids and anti-glucocorticoids
also up-regulate human CYP 3A4 levels by this way [28]. The
similarities between DEX-related regulations of rat CYP 3A1/
2 and MRP2 strongly favor the idea that PXR might play a
role in glucocorticoid-mediated induction of MRP2. This hy-
pothesis is moreover supported by the facts that (1) a putative
consensus sequence for PXR, i.e. two copies of the nuclear
receptor half site sequence TGAACT organized as an everted
repeat and separated by 8 bp, is present in the promoter of the
rat MRP2 gene at position 3404 [29] and (2) clotrimazole and
PCN, two known activators of PXR [28], were demonstrated
to up-regulate MRP2 expression. In addition, we have de-
tected substantial levels of PXR mRNAs in primary rat hep-
atocytes (data not shown), suggesting that PXR is well ex-
pressed in such cells. Further studies are therefore required
to validate the putative involvement of PXR in DEX-medi-
ated regulation of MRP2.
Dexamethasone and other glucocorticoids are drugs com-
monly used in patients, often in multicombination therapy,
and the up-regulation of MRP2 expression that they may
induce may increase MRP2-dependent biliary secretion of
co-administered drugs, therefore potentially altering the e⁄-
cacy of these compounds. Elimination of physiologically im-
portant substrates for MRP2 such as leukotriene C4 and bil-
irubin glucuronides may also be enhanced. In this context, it
may be noteworthy that DEX treatment has been reported to
up-regulate elimination of the contrast agent ioglycemic acid
[30] and also to decrease bilirubin levels in some patients [31].
In addition, administration of DEX to rats has been recently
shown to increase MRP2 expression in kidney [32], therefore
suggesting that MRP2-mediated renal elimination of drugs
may also be altered in response to glucocorticoids. It is how-
ever noteworthy that the doses of DEX that maximally induce
MRP2 expression in primary hepatocytes are super-physiolog-
ical, therefore suggesting that endogenous glucocorticoids
may contribute to in vivo MRP2 regulation in a limited man-
ner.
In summary, the present study indicates that DEX is a
potent inducer of MRP2 expression in rat hepatocytes,
Fig. 6. E¡ect of clotrimazole and PCN on MRP2 mRNA levels in
primary rat hepatocytes. Each lane contained 10 Wg total RNAs iso-
lated from primary rat hepatocytes either untreated (UNT) or ex-
posed to 2U1035 M clotrimazole (CLO) or to 2U1035 M PCN.
RNAs were transferred to Hybond N+ sheets after electrophoresis
and hybridized with MRP2 and 18S probes.
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through a mechanism that requires active transcription and
likely does not involve the classical GR pathway.
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